- Home
- FCN vs BPMC Comparison
FCN vs BPMC Comparison
Compare FCN & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCN
- BPMC
- Stock Information
- Founded
- FCN 1982
- BPMC 2008
- Country
- FCN United States
- BPMC United States
- Employees
- FCN N/A
- BPMC N/A
- Industry
- FCN Professional Services
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- FCN Consumer Discretionary
- BPMC Health Care
- Exchange
- FCN Nasdaq
- BPMC Nasdaq
- Market Cap
- FCN 7.2B
- BPMC 5.9B
- IPO Year
- FCN 1996
- BPMC 2015
- Fundamental
- Price
- FCN $196.87
- BPMC $96.15
- Analyst Decision
- FCN Strong Buy
- BPMC Buy
- Analyst Count
- FCN 1
- BPMC 20
- Target Price
- FCN $275.00
- BPMC $120.79
- AVG Volume (30 Days)
- FCN 188.0K
- BPMC 587.2K
- Earning Date
- FCN 10-24-2024
- BPMC 10-30-2024
- Dividend Yield
- FCN N/A
- BPMC N/A
- EPS Growth
- FCN 28.86
- BPMC N/A
- EPS
- FCN 8.71
- BPMC N/A
- Revenue
- FCN $3,728,412,000.00
- BPMC $434,415,000.00
- Revenue This Year
- FCN $7.62
- BPMC $108.09
- Revenue Next Year
- FCN $5.01
- BPMC $39.34
- P/E Ratio
- FCN $22.87
- BPMC N/A
- Revenue Growth
- FCN 11.66
- BPMC 100.93
- 52 Week Low
- FCN $185.93
- BPMC $72.24
- 52 Week High
- FCN $243.60
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- FCN 40.07
- BPMC 53.72
- Support Level
- FCN $196.40
- BPMC $91.88
- Resistance Level
- FCN $201.97
- BPMC $97.44
- Average True Range (ATR)
- FCN 3.94
- BPMC 2.65
- MACD
- FCN 0.06
- BPMC -0.27
- Stochastic Oscillator
- FCN 10.79
- BPMC 57.49
About FCN FTI Consulting Inc.
FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance and restructuring, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.